07:35 AM EDT, 10/28/2024 (MT Newswires) -- Biogen (BIIB) said late Saturday that a phase 2 clinical trial assessing felzartamab demonstrated "substantial reductions" in proteinuria levels, stabilization of kidney function, and sustained treatment impact over 18 months following the investigational drug's last dose.

The trial enrolled 54 participants to evaluate felzartamab's safety and efficacy in patients with Immunoglobulin A nephropathy and high risk of progressive kidney dysfunction, the company said.

Felzartamab was "generally well tolerated" with a safety profile "consistent" with previous trials, Biogen added.

Price: 182.59, Change: +0.90, Percent Change: +0.50